Report : South America Lyophilized Injectable Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Type of Packaging (Single-Use Vials, Point-of-Care Reconstitution, and Specialty Packaging), Type of Delivery (Prefilled Diluent Syringes, Single-Step Devices, Proprietary Reconstitution Devices, and Multi-Step Devices), Indication (Metabolic and Oncology Conditions, Infectious Diseases, Autoimmune Diseases, and Others), and End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, and Others)
At 4.6% CAGR, the SAM Lyophilized Injectable Market is speculated to be worth US$ 181.45 million by 2028, says Business Market Insights
According to Business Market Insights' research, the SAM lyophilized injectable market was valued at US$ 138.84 million in 2022 and is expected to reach US$ 181.45 million by 2028, registering a CAGR of 4.6% from 2022 to 2028. Advancement in lyophilized packaging and expansion of pipeline of lyophilized injectable drugs are the critical factors attributed to the market expansion.
The complexity of drug reconstitution constrained the market potential for lyophilized drugs and vaccines. With multiple pieces of device and long procedures required to reconstitute a lyophilized drug from a vial, thus, most of these products are restricted within healthcare facilities. However, the healthcare transformation toward patient self-injection and the acceleration after biologics flared a new wave of creation for drug reconstitution technology. Dual-chamber syringes represent an enabling technology for both self-injection of lyophilized drugs and for new therapies directing the mixing of two liquid molecules at the time of drug delivery. Prefilled dual chamber devices (DCDs) are combination device containing freeze-dried drugs and diluent in two separate chambers of the device. DCDs have shown many advantages as compared to the traditional drug-delivery systems, such as easy handling, accurate dosing, seal integrity, and high stability, and therefore are promising alternatives to these traditional drug-delivery systems. DCDs are becoming popular choices for physicians and patients needing instant relief and safe delivery, significantly improving drug delivery by quickly applying pressure to the end plunger after mixing and dissolving freeze-dried powder. DCDs can improve long-term pharmaceutical stability by storing them in the lyophilized form before administration and therefore are becoming more popular, especially for those unstable pharmaceutical products. Therefore, advancement in lyophilized packaging is expected to drive the market across the region.
On the contrary, growing rate of product recalls hurdles the growth of SAM lyophilized injectable market.
Based on type of packaging, the SAM lyophilized injectable market is segmented into single-use vials, point-of-care reconstitution, and specialty packaging. The single-use vials segment held 49.3% market share in 2022, amassing US$ 68.42 million. It is projected to garner US$ 89.13 million by 2028 to expand at 4.5% CAGR during 2022-2028.
Based on type of delivery, the SAM lyophilized injectable market is segmented into prefilled diluent syringes, single-step devices, proprietary reconstitution devices, and multi-step devices. The prefilled diluent syringes segment held 42.7% market share in 2022, amassing US$ 59.24 million. It is projected to garner US$ 79.80 million by 2028 to expand at 5.1% CAGR during 2022-2028.
Based on indication, the SAM lyophilized injectable market is segmented into metabolic and oncology conditions, infectious diseases, autoimmune diseases, and others. The metabolic and oncology conditions segment held 46.5% market share in 2022, amassing US$ 64.53 million. It is projected to garner US$ 86.36 million by 2028 to expand at 5.0% CAGR during 2022-2028.
Based on end user, the SAM lyophilized injectable market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others. The hospitals segment held 47.0% market share in 2022, amassing US$ 65.28 million. It is projected to garner US$ 85.96 million by 2028 to expand at 4.7% CAGR during 2022-2028.
Based on country, the SAM lyophilized injectable market has been categorized into Brazil, Argentina, and the Rest of SAM. Our regional analysis states that Brazil captured 55.3% market share in 2022. It was assessed at US$ 76.74 million in 2022 and is likely to hit US$ 104.67 million by 2028, exhibiting a CAGR of 5.3% during the forecast period.
Key players dominating the SAM lyophilized injectable market are Aristopharma Ltd.; Baxter; Credence MedSystems, Inc.; Jubilant HollisterStier (Jubilant Pharma Limited); Nipro; Recipharm AB; S.G. Biopharm Pvt. Ltd.; and Vetter Pharma among others.
In Oct 2020, Credence MedSystems and SCHOTT AG have formed a collaboration for the application of Credence Companion technology with SCHOTT's pre-fillable syriQ glass and SCHOTT TOPPAC polymer syringe systems. The two companies will work together to integrate the technologies and provide the pharmaceutical industry with an innovative and differentiated offering for the delivery of injectable medications via prefilled syringes.
In Jan 2021, Novartis has invested in Credence, confirming its interest in employing Credence technology for its injectable medicines. The investment is geared towards supporting Credence's ramp-up of manufacturing capacity for its innovative drug delivery systems and enabling commercial supply of Credence devices to the pharmaceutical market.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com